All In Biotech

Drug Trial Radar · NCT06793397

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Dec 10, 2025

Primary completion

Jun 7, 2027

Study completion Aug 9, 2027

Sponsor

Lead sponsor
Cybin IRL LimitedIndustry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Conditions

  • Major Depressive Disorder (MDD)
  • Depression in Adults
  • Depression - Major Depressive Disorder
  • Depression Disorders
  • Depression Disorder
  • Depression

Interventions

  • CYB003Drug

    CYB003 is a deuterated psilocin analog.

  • Psychological SupportBehavioral

    Manualized psychological support performed by facilitator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Montgomery-Asberg Depression Scale (MADRS)Time frame: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

Locations

79 sites in 8 countries. Site status is shown where the registry gives one.

  • UAB Psychiatry and Behavioral Neurology

    Birmingham, Alabama · Recruiting

  • Lighthouse Psychiatry

    Gilbert, Arizona · Recruiting

  • Pillar Clinical Research - Little Rock

    Little Rock, Arkansas · Withdrawn

  • Behavioral Research Specialists, LLC

    Glendale, California · Recruiting

  • Sun Valley Research Center

    Imperial, California · Withdrawn

  • CalNeuro Research Group

    Los Angeles, California · Recruiting

  • Lipov Medical Group

    Los Angeles, California · Recruiting

  • ATP Clinical Research

    Orange, California · Recruiting

  • NRC Research Institute

    Orange, California · Recruiting

  • Inland Psychiatric Medical Group Inc (IPMG Research)

    San Juan Capistrano, California · Recruiting

  • Psychedelic Science Institute

    Santa Monica, California · Recruiting

  • Stanford University

    Stanford, California · Withdrawn

  • Yale School of Medicine - Yale Program for Psychedelic Science

    New Haven, Connecticut · Recruiting

  • CNS Healthcare

    Jacksonville, Florida · Recruiting

  • Accel Research Sites - Maitland

    Maitland, Florida · Recruiting

  • Aqualane Clinical Research

    Naples, Florida · Recruiting

  • K2 Medical Research Tampa

    Tampa, Florida · Recruiting

  • Emory University Dept of Psychiatry and Behavioral Studies

    Atlanta, Georgia · Withdrawn

  • Psych Atlanta

    Marietta, Georgia · Recruiting

  • Rush University

    Chicago, Illinois · Recruiting

  • Tandem Clinical Research

    Marrero, Louisiana · Withdrawn

  • Atlas Psychiatry

    New Orleans, Louisiana · Recruiting

  • Johns Hopkins Medicine

    Baltimore, Maryland · Withdrawn

  • Sunstone Medical, PC

    Rockville, Maryland · Not yet recruiting

  • Adams Clinical Boston

    Boston, Massachusetts · Recruiting

  • Adams Clinical Watertown

    Watertown, Massachusetts · Recruiting

  • Institute for Integrative Therapies

    Eden Prairie, Minnesota · Recruiting

  • The Remedy Mental Health

    Golden Valley, Minnesota · Not yet recruiting

  • Redbird Research, LLC

    Las Vegas, Nevada · Recruiting

  • Bio Behavioral Health

    Toms River, New Jersey · Recruiting

  • Adams Clinical Harlem

    New York, New York · Recruiting

  • New York State Psychiatric Institute

    New York, New York · Not yet recruiting

  • Adams Clinical Bronx

    The Bronx, New York · Recruiting

  • SP Research PLLC

    Oklahoma City, Oklahoma · Withdrawn

  • Adams Clinical Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Flourish Research Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Austin Clinical Trial Partners

    Austin, Texas · Withdrawn

  • Adams Clinical Dallas

    DeSoto, Texas · Recruiting

  • North Texas Clinical Trials

    Fort Worth, Texas · Withdrawn

  • Brain Health Consultants and TMS Center

    Houston, Texas · Recruiting

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.